Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rapamycin Holdings Inc.
HonorHealth Research Institute
University of Michigan Rogel Cancer Center
Recursion Pharmaceuticals Inc.
Assistance Publique Hopitaux De Marseille
Abramson Cancer Center at Penn Medicine
Instituto do Cancer do Estado de São Paulo
Odense University Hospital
Johns Hopkins University
Janssen Research & Development, LLC
University Hospital, Toulouse
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Shanghai Zhongshan Hospital
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Yonsei University
Universitätsklinikum Hamburg-Eppendorf
S.L.A. Pharma AG
University Medical Center Groningen
Peking Union Medical College Hospital
Janssen Research & Development, LLC
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Yonsei University
Cancer Prevention Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
Pfizer
Charite University, Berlin, Germany
Charite University, Berlin, Germany
University of Puerto Rico
National Cancer Institute (NCI)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Tel-Aviv Sourasky Medical Center
Yonsei University
Vanderbilt-Ingram Cancer Center
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
W.L.Gore & Associates
Ohio State University Comprehensive Cancer Center
Tel-Aviv Sourasky Medical Center
University of Utah
Cancer Prevention Pharmaceuticals, Inc.
Tel-Aviv Sourasky Medical Center
Integra LifeSciences Corporation
S.L.A. Pharma AG
Tel-Aviv Sourasky Medical Center
King Chulalongkorn Memorial Hospital
Radboud University Medical Center